Prevention of restenosis and of cardiac events after coronary angioplasty in diabetics
Nyssen, A.; Legrand, V.; Scheen, A.J.
Revue Medicale Suisse 5(214): 1638-1643
2009
ISSN/ISBN: 1660-9379 PMID: 19772194 Document Number: 14330
Various systemic pharmacological approaches have been evaluated to reduce the risk of restenosis and clinical complications after coronary angioplasty, with or without stent, a main objective in the high risk diabetic population. The aim of the present paper is to describe the effects of the main pharmacological classes on the risk of restenosis, the need for new revascularisation procedures and the incidence of major clinical events (MACE: death, myocardial infarction, revascularisation). We will analyse successively the role of antiplatelet agents, omega 3 fatty acids, statins, anti-inflammatory compounds, immunomodulators, anti-oxidants and inhibitors of the renin-angiotensin system. Whenever possible, we will focus our attention on the results obtained in the diabetic population.
Document emailed within 1 workday
